Application for FDA Approval to Market a New Drug

Forms and Documents

Document	Type	Status	Availability

No forms / supporting documents in this ICR. Check IC Document Collections.

IC Document Collections

IC ID	Collection	Type	Status	Form
5660	Application for FDA Approval to Market a New Drug		Migrated

ICR Details

OMB Control No: 0910-0001	ICR Reference No: 199809-0910-006
Status: Historical Active	Previous ICR Reference No: 198906-0910-021
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Application for FDA Approval to Market a New Drug
Type of Information Collection: Reinstatement without change of a previously approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 11/18/1998
	Date Received in OIRA: 09/25/1998
Terms of Clearance: Approval for this collection expired 11/30/99 and has been in use without an OMB number for nearly 10 years. This is an egregious violation of the Paperwork Reduction Act and FDA shall take steps to ensure that such a violation shall not occur in the future. In addition, as a condition of clearance, FDA shall provide OMB within the next two weeks documentation substantiating the revised burden estimates.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	03/31/2002	03/31/2002
Responses	21,200	0	0
Time Burden (Hours)	2,121,270	0	0
Cost Burden (Dollars)	0	0	0

---

Abstract: Under section 505 of the Federal Food, Drug, and Cosmetic Act (the Act), a new drug may not be commercially marketed in the United States, imported, or exported from the United States unless it has been approved as safe and effective by FDA. Such approval is based on a New Drug Application (NDA) submitted, under 21 CFR part 314, by the sponsor of the drug, containing acceptable scientific data, including the results of tests to evaluate its safety, and substantial evidence of effectiveness for the conditions for which the drug is to be offered. Under the Act, it is the sponsor's responsibility to provide....

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:

---

Federal Register Notices & Comments

Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Application for FDA Approval to Market a New Drug

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	21,200	0	0	21,200	0	0
Annual Time Burden (Hours)	2,121,270	0	0	2,121,270	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/25/1998

---